Praxis Medical Insights

Est. 2024 • Clinical Guidelines Distilled

Made possible by volunteer editors from the University of Calgary & University of Alberta

Last Updated: 8/31/2025

Treatment of Insomnia in Patients with CPTSD and Severe Refractory Somatic Anxiety

First-Line Treatment: Psychological and Behavioral Approaches

  • The American Academy of Sleep Medicine recommends Cognitive Behavioral Therapy for Insomnia (CBT-I) as the first-line treatment for insomnia related to CPTSD and severe refractory somatic anxiety, with strong evidence for efficacy in patients with psychiatric comorbidities 1, 2
  • CBT-I components should include cognitive therapy to address distorted beliefs about sleep, stimulus control to strengthen the association between bed and sleep, sleep restriction therapy to improve sleep efficiency, sleep hygiene education, and relaxation techniques 1, 2, 3
  • For trauma-related nightmares specifically, add specialized techniques such as Exposure, Relaxation, and Rescripting Therapy (ERRT), progressive muscle relaxation training, and image rehearsal therapy for PTSD-associated nightmares 1, 4, 5

Second-Line Treatment: Pharmacological Options

  • The American Academy of Sleep Medicine suggests that low-dose sedating antidepressants, such as trazodone (25-50mg) or doxepin (3-6mg), can be considered for insomnia in patients with anxiety disorders if CBT-I is insufficient after 2-4 weeks 2, 4
  • Gabapentin (doses around 1300mg) has shown moderate to marked improvement in insomnia and nightmares in PTSD patients and can be considered for patients with significant somatic anxiety components 6

Treatment Algorithm

  • The initial approach should begin with CBT-I as the foundation of treatment, with documentation of sleep patterns using a sleep log to track progress 1, 2
  • After 2-4 weeks, if insufficient improvement, continue CBT-I and add low-dose trazodone (25-50mg) or doxepin (3-6mg), or consider adding prazosin or implementing specialized nightmare therapies for prominent nightmares 2, 4, 5

Important Considerations and Pitfalls

  • The American Academy of Sleep Medicine advises avoiding benzodiazepines as first-line therapy due to risk of dependence, abuse potential, and cognitive impairment, and being cautious with long-term use of sedative-hypnotics as they can lose efficacy over time and lead to dependence 2, 4
  • Regular reassessment of sleep patterns is essential to evaluate treatment efficacy, and sleep disordered breathing may be more common in PTSD patients and should be considered if insomnia persists despite treatment 2

REFERENCES

1

clinical guideline for the evaluation and management of chronic insomnia in adults. [LINK]

Journal of clinical sleep medicine : JCSM : official publication of the American Academy of Sleep Medicine, 2008

2

Management of Insomnia in Patients with Comorbid Conditions [LINK]

Praxis Medical Insights: Practical Summaries of Clinical Guidelines, 2025

3

clinical guideline for the evaluation and management of chronic insomnia in adults. [LINK]

Journal of clinical sleep medicine : JCSM : official publication of the American Academy of Sleep Medicine, 2008

5

position paper for the treatment of nightmare disorder in adults: an american academy of sleep medicine position paper. [LINK]

Journal of clinical sleep medicine : JCSM : official publication of the American Academy of Sleep Medicine, 2018

6

position paper for the treatment of nightmare disorder in adults: an american academy of sleep medicine position paper. [LINK]

Journal of clinical sleep medicine : JCSM : official publication of the American Academy of Sleep Medicine, 2018